MONTREAL, Sept. 26 /PRNewswire-FirstCall/ -- CryoCath Technologies Inc. (TSX: CYT), the global leader in cryotherapy products to treat cardiovascular disease, today announced that Henri Vienneau, Interim President and CEO of the Company, will present at the 2006 UBS Global Life Sciences Conference in New York on Thursday, September 28, at 8:00a.m. EDT.
A live audio webcast of CryoCath's presentation will be available at http://www.cryocath.com/ or on the UBS website. To access the webcast on the UBS site:
- Go to http://www.ibb.ubs.com/
- Find the Conferences box in the middle of the page (last box on the
right)
- Click on the graphic link
- Follow link for webcast next to the 2006 Global Life Sciences
Conference
About CryoCath
CryoCath - http://www.cryocath.com/ - is a medical technology company that leads the world in cryotherapy products to treat cardiovascular disease. With a priority focus on providing physicians with a complete solution of catheter and surgical products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias and has development projects for the treatment of cardiac ischemia (angina) and peripheral arterial disease (PAD).
This press release includes "forward-looking statements" that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath's annual report available at http://www.sedar.com/ under the heading Risks and Uncertainties in the Management's Discussion and Analysis section.
